Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

Sadia Zafar; Dafne Carolina Alves Quixabeira; Tatiana Viktorovna Kudling; Victor Cervera-Carrascon; Joao Manuel Santos; Susanna Grönberg-Vähä-Koskela; Fang Zhao; Pasi Aronen; Camilla Heiniö; Riikka Havunen; Suvi Sorsa; Anna Kanerva; Akseli Hemminki

doi:10.1038/s41417-020-00226-z

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

Sadia Zafar, Dafne Carolina Alves Quixabeira, Tatiana Viktorovna Kudling, Victor Cervera-Carrascon, Joao Manuel Santos, Susanna Grönberg-Vähä-Koskela, Fang Zhao, Pasi Aronen, Camilla Heiniö, Riikka Havunen, Suvi Sorsa, Anna Kanerva, Akseli Hemminki

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Cancer Gene Therapy
Volume	28
Issue number	5
Pages (from-to)	442-454
Number of pages	13
ISSN	0929-1903
DOIs	https://doi.org/10.1038/s41417-020-00226-z
Publication status	Published - May 2021
MoE publication type	A1 Journal article-refereed

Fields of Science

PHASE-I TRIAL
ONCOLYTIC ADENOVIRUS
CANCER-PATIENTS
GENE-TRANSFER
CLINICAL-TRIAL
OVARIAN-CANCER
DESMOGLEIN 2
VIRUS
RECEPTOR
FIBER
3122 Cancers
3111 Biomedicine
318 Medical biotechnology
11832 Microbiology and virology
1184 Genetics, developmental biology, physiology

Access to Document

10.1038/s41417-020-00226-z

s41417-020-00226-zFinal published version, 1.8 MBLicence: CC BY

Cite this

Zafar, S., Quixabeira, D. C. A., Kudling, T. V., Cervera-Carrascon, V., Santos, J. M., Grönberg-Vähä-Koskela, S., Zhao, F., Aronen, P., Heiniö, C., Havunen, R., Sorsa, S., Kanerva, A., & Hemminki, A. (2021). Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. Cancer Gene Therapy, 28(5), 442-454. https://doi.org/10.1038/s41417-020-00226-z

@article{03db0da2a4e04dbea0fd95b973c7615c,

title = "Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes",

keywords = "PHASE-I TRIAL, ONCOLYTIC ADENOVIRUS, CANCER-PATIENTS, GENE-TRANSFER, CLINICAL-TRIAL, OVARIAN-CANCER, DESMOGLEIN 2, VIRUS, RECEPTOR, FIBER, 3122 Cancers, 3111 Biomedicine, 318 Medical biotechnology, 11832 Microbiology and virology, 1184 Genetics, developmental biology, physiology",

author = "Sadia Zafar and Quixabeira, {Dafne Carolina Alves} and Kudling, {Tatiana Viktorovna} and Victor Cervera-Carrascon and Santos, {Joao Manuel} and Susanna Gr{\"o}nberg-V{\"a}h{\"a}-Koskela and Fang Zhao and Pasi Aronen and Camilla Heini{\"o} and Riikka Havunen and Suvi Sorsa and Anna Kanerva and Akseli Hemminki",

year = "2021",

month = may,

doi = "10.1038/s41417-020-00226-z",

language = "English",

volume = "28",

pages = "442--454",

journal = "Cancer Gene Therapy",

issn = "0929-1903",

publisher = "NATURE PUBLISHING GROUP",

number = "5",

}

TY - JOUR

T1 - Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

AU - Zafar, Sadia

AU - Quixabeira, Dafne Carolina Alves

AU - Kudling, Tatiana Viktorovna

AU - Cervera-Carrascon, Victor

AU - Santos, Joao Manuel

AU - Grönberg-Vähä-Koskela, Susanna

AU - Zhao, Fang

AU - Aronen, Pasi

AU - Heiniö, Camilla

AU - Havunen, Riikka

AU - Sorsa, Suvi

AU - Kanerva, Anna

AU - Hemminki, Akseli

PY - 2021/5

Y1 - 2021/5

KW - PHASE-I TRIAL

KW - ONCOLYTIC ADENOVIRUS

KW - CANCER-PATIENTS

KW - GENE-TRANSFER

KW - CLINICAL-TRIAL

KW - OVARIAN-CANCER

KW - DESMOGLEIN 2

KW - VIRUS

KW - RECEPTOR

KW - FIBER

KW - 3122 Cancers

KW - 3111 Biomedicine

KW - 318 Medical biotechnology

KW - 11832 Microbiology and virology

KW - 1184 Genetics, developmental biology, physiology

U2 - 10.1038/s41417-020-00226-z

DO - 10.1038/s41417-020-00226-z

M3 - Article

SN - 0929-1903

VL - 28

SP - 442

EP - 454

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

IS - 5

ER -